Back to top
more

YmAbs Therapeutics (YMAB)

(Delayed Data from NSDQ)

$15.69 USD

15.69
303,801

+0.59 (3.91%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $15.66 -0.03 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

by Zacks Equity Research

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -10.00% and -15.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.06% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.95% and -91.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?